Tag Archives: hypertriglyceridaemia

Hypertriglyceridaemia: apoC-III inhibition comes of age Professor Maciej Banach (Medical University of Łódź, Poland) Professor Maciej Banach (Medical University of Łódź, Poland) opened with Olezarsen, an antisense oligonucleotide targeting APOC3 messenger RNA that accelerates clearance of triglyceride-rich remnants. In ESSENCE-TIMI 73b (phase 3, n=1,349), it lowered triglycerides by around 60% at six months in moderate hypertriglyceridaemia, with most patients reaching a level below 1.7 mmol/L.1 In the separate CORE-TIMI 72a and CORE2-TIMI 72b trials in severe hypertriglyceridaemia, adjudicated acute pancreatitis was significantly les

Introduction Multiple epidemiologic studies have identified elevated levels of blood triglycerides (TGs) or the phenotypic state of hypertriglyceridaemia (HTG) as being associated with an elevated risk of cardiovascular (CV) disease.1 Among therapies demonstrating significant reduction in TGs – beyond fibrates, niacin and statins – are marine-derived omega-3 polyunsaturated fatty acids (n-3 PUFAs); they consist principally of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Notably, the first Gruppo Italiano per lo Studio della Streptochiansi nell’Infarto (GISSI) supported a potential role of n-3 PUFAs in reducing death, non-